Drug Type Peptibody, Biosimilar |
Synonyms Romiplostim Biosimilar (Paras Biopharmaceuticals Finland Oy), 罗米司亭生物类似药(Paras Biopharmaceuticals Finland Oy), PB (CT) 4020 + [2] |
Target |
Action agonists |
Mechanism TPO receptor agonists(Thrombopoietin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |

| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D08990 | Romiplostim Biosimilar (Paras Biopharmaceuticals) |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Blood Platelet Disorders | Preclinical | Finland | 06 May 2024 |






